Find the Perfect Plan for Your Investment Journey
Latest price
52 Week Range
$3.56 - $12.92
Next Earnings Date
May 08 2025
Next Earnings Date
May 08 2025
Latest price
Market Cap | $293.46M |
EV | $66.00M |
Shares Outstanding | 58.01M |
Beta | 0.68 |
Analyst Rating | BUY |
Analyst Target Price | $26.50 |
P/E 2025E | - |
P/Revenue 2025E | - |
Revenue | - |
EPS | 59.10% |
Operating Cash Flow | -39.10% |
Free Cash Flow | -69.60% |
Revenue | - |
EPS | -5.80% |
Operating Cash Flow | - |
Free Cash Flow | -36.30% |
Gross Margin 2025E | 0.00% |
Net Profit Margin 2025E | - |
ROE 2025E | - |
ROCE 2024 | -50.71% |
DPS 2025E | - |
Payout Ratio 2025E | - |
Div. Yield 2025E | - |
DPS Last 3Y CAGR | - |
Price
%
1M
3M
6M
1Y
3Y
5Y
Astria Therapeutics, Inc.
ATXS
Sector
Healthcare
Industry
Biotechnology
CEO
Milne, Jill
Employees
78
Website
www.astriatx.comIPO Date
2015-06-25
Headquarters
75 State Street, Suite 1400, Boston, Massachusetts, 02109, United States
COMPANY
NEWSLETTER
© Copyright 2025, All Rights Reserved